Current President and CEO, Earl Fender, announces retirement
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer.
This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months.
Mr. West remarked, “I am very excited and honored to be leading Nalu. I believe Nalu’s unique system and technology, including the miniaturized, battery-free implantable pulse generator with its broad capabilities, upgradability and industry leading longevity are going to meaningfully expand the number of chronic pain patients who can benefit from both Spinal Cord and Peripheral Nerve Stimulation. Nalu is poised for rapid growth, and I am eager to join the company and to build upon the strong foundation it has established.”
Mr. Fender added, “I am proud of the Nalu team and what we have accomplished to date. The company is in a strong position and the timing is right for me to retire. We are very fortunate to have someone of Tom’s caliber joining the team. Tom has a proven track record of leading and building strong teams during high periods of growth. He has more than 30 years of medical device leadership experience, including as Division President, Diagnostic Solutions at Hologic, and most recently as the President and CEO of Intersect ENT (NASDAQ: XENT) prior to its recent sale to Medtronic. Tom began his healthcare career at Johnson & Johnson and serves as an independent member of the board of directors at Orthofix. He is very focused on customers and clinical outcomes, which are at the heart of Nalu’s success.”
Speaking on behalf of the Board, its Chairman, Geoff Pardo, said, “we are very grateful for Earl’s leadership, particularly in leading the recent $104M equity financing and establishing a strong foundation for the company’s continued growth. We wish him well in his retirement. The Board is very excited that Tom has joined the company. He is a visionary leader and we believe his commercial and operational skills and experience are what Nalu needs for its next phase of growth.”
About Nalu Medical
Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu system was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.
About the Nalu Neurostimulation System
The Nalu system consists of a fully-featured, battery-free, miniaturized implantable pulse generator (IPG) that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote control app. Despite its small size, Nalu’s micro-IPGTM delivers treatment capabilities similar to larger IPGs as well as unique advantages associated with advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years. The Nalu System has been repeatedly recognized for its revolutionary technology, including being named as one of the world’s top 100 new products by R&D Magazine in 2021. It is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit www.nalumed.com.
Indications for Use
Spinal Cord Stimulation – The Nalu SCS system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Peripheral Nerve Stimulation – The Nalu PNS system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Nalu, micro-IPG and the Nalu logo are trademarks of Nalu Medical, Inc.